natgillin/translations-raw huggingface dataset:
Dose modifications should be made if patients experience the following adverse reactions (Grades refer to Common Terminology Criteria for Adverse Events [CTCAE 4.0]): Table 1 - Recommended dose modifications for adverse reaction in patients treated with cabazitaxel 
Dozu je potrebno prilagoditi ako se u bolesnika pojave sljedeće nuspojave (stupnjevi su određeni prema verziji 4,0 Zajedničkih terminoloških kriterija za nuspojave (engl.
Premedication The recommended premedication regimen should be performed at least 30 minutes prior to each administration of JEVTANA with the following intravenous medicinal products to mitigate the risk and severity of hypersensitivity: 
Radi smanjivanja rizika i težine reakcija preosjetljivosti, potrebno je primijeniti preporučenu premedikaciju najmanje 30 minuta prije svake primjene lijeka JEVTANA i to intravenskom primjenom sljedećih lijekova:
From a microbiological point of view, the concentrate-solvent mixture should be used immediately. 
S mikrobiološkog stajališta, pripremljenu otopinu koncentrata i otapala treba primijeniti odmah.
One ml of concentrate contains 40 mg cabazitaxel. 
Jedan ml koncentrata sadrži 40 mg kabazitaksela.
If co-administration with a strong CYP3A inhibitor cannot be avoided, close monitoring for toxicity and a cabazitaxel dose reduction should be considered (see sections 4.2 and 4.5). 
Ako se ne može izbjeći istodobna primjena sa snažnim inhibitorima CYP3A, potrebno je pomno pratiti toksičnost te razmotriti smanjenje doze kabazitaksela (vidjeti dijelove 4.2 i 4.5).
Psychiatric disorders Anxiety Confusional state Nervous system Dysgeusia 
Psihijatrijski poremećaji anksioznost smetenost
Delay treatment until improvement or resolution, and until neutrophil count is >1,500 cells/mm3, then reduce cabazitaxel dose from 25 mg/m2 to 
Febrilna neutropenija ili neutropenijska infekcija Odgoditi liječenje do poboljšanja ili oporavka te dok broj neutrofila ne dosegne > 1500 stanica/mm3, a zatim smanjiti dozu kabazitaksela s 25 mg/m2 na 20 mg/m2.
Vistor hf. 
1 HR (engl.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). 
Lijek se izdaje na ograničeni recept (vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2)
Ear and labyrinth disorders 
Poremećaji uha i labirinta tinitus vrtoglavica
• you are allergic (hypersensitive) to cabazitaxel, to other taxanes, or polysorbate 80 or any of the other excipients of this medicine (listed in section 6), 
• ako ste alergični (preosjetljivi) na kabazitaksel, druge taksane ili polisorbat 80 ili neki drugi sastojak ovog lijeka (naveden u dijelu 6), • ako imate premalo bijelih krvnih stanica (broj neutrofila manji ili jednak 1500/mm3)
Step 1.3 
Korak 1.3
NAME OF THE MEDICINAL PRODUCT JEVTANA 60 mg concentrate and solvent for solution for infusion. 
JEVTANA 60 mg koncentrat i otapalo za otopinu za infuziju.
Step 2.2 
Korak 2.2
There was no significant difference in overall survival in this group of patients (HR (95%CI) 0.96 (0.49-1.86)). 
(HR (95% CI): 0,96 (0,49-1,86)).
Grade >2 peripheral neuropathy 
Periferna neuropatija stupnja ≥ 2
Leukopeniaa 
Proljev
All patients should be pre-medicated prior to the initiation of the infusion of cabazitaxel (see section 4.2). 
U svih je bolesnika potrebno provesti premedikaciju prije početka primjene infuzije kabazitaksela
Delay treatment until improvement or resolution, then reduce cabazitaxel dose from 25 mg/m2 to 
Odgoditi liječenje do poboljšanja ili oporavka, a zatim smanjiti dozu kabazitaksela s 25 mg/m2 na 20 mg/m2.
Step 1.2 
Korak 1.2
Each 1.5 ml vial of concentrate contains 60 mg cabazitaxel. 
Jedna bočica s 1,5 ml koncentrata sadrži 60 mg kabazitaksela.
NAME OF THE MEDICINAL PRODUCT JEVTANA 60 mg concentrate and solvent for solution for infusion cabazitaxel 
JEVTANA 60 mg koncentrat i otapalo za otopinu za infuziju kabazitaksel
Inspect the concentrate vial and the supplied solvent. 
Pregledajte bočicu s koncentratom lijeka i priloženo otapalo.
Step 1.4 
Korak 1.4
• Concentrate: 1.5 ml of concentrate in a 15 ml clear glass vial (type I) closed with a grey chlorobutyl rubber closure sealed by an aluminium cap covered with a light green plastic flip-off cap. Each vial contains 60 mg cabazitaxel per 1.5 ml nominal volume (fill volume: 73.2 mg of cabazitaxel/1.83 ml). 
• koncentrat: 1,5 ml koncentrata u prozirnoj staklenoj bočici od 15 ml (staklo tip I), zatvorenoj sivim gumenim zatvaračem (klorobutil guma), aluminijskim prstenom i svijetlozelenim plastičnim
Upper respiratory tract infection Herpes zoster Candidiasis 
Infekcije i infestacije septički šok sepsa celulitis infekcija mokraćnih putova gripa cistitis infekcija gornjih dišnih putova herepes zoster kandidijaza
This overfill ensures that after dilution with the ENTIRE contents of the accompanying solvent, there is solution containing 10 mg/ml cabazitaxel. 
Dodatna količina osigurava da se nakon razrjeđenja CJELOKUPNIM sadržajem priloženog otapala postigne koncentracija pripremljene otopine od 10 mg/ml kabazitaksela.
This overfill ensures that after initial dilution with the ENTIRE content of the solvent vial, the concentration of cabazitaxel is 10 mg/ml. 
Dodatna količina punjenja osigurava da nakon početnog razrjeđenja CJELOKUPNIM sadržajem bočice otapala koncentracija kabazitaksela bude 10 mg/ml.
Step 1.1 
Korak 1.1
The safety of JEVTANA in combination with prednisone or prednisolone was evaluated in 371 patients with metastatic castration resistant prostate cancer who were treated with 25 mg/m2 
Sažetak sigurnosnog profila Sigurnost primjene lijeka JEVTANA u kombinaciji s prednizonom ili prednizolonom ocijenjena je u randomiziranom, otvorenom, kontroliranom kliničkom ispitivanju faze III na 371 bolesniku s metastatskim karcinomom prostate rezistentnim na kastraciju liječenom kabazitakselom u dozi od 25 mg/m2 jedanput svaka 3 tjedna.
System Organ Class Adverse reaction 
Klasifikacije organskih sustava
Neuropathy peripheral Peripheral sensory neuropathy Dizziness Headache Paraesthesia Lethargy 
Poremećaji živčanog sustava disgeuzija periferna neuropatija periferna senzorna neuropatija omaglica glavobolja parestezije
Aseptically withdraw the required amount of concentrate-solvent mixture (10 mg/ml of cabazitaxel), with a graduated syringe fitted with a needle. 
Pomoću graduirane štrcaljke s iglom aseptički izvucite odgovarajući volumen mješavine koncentrata i otapala (10 mg/ml kabazitaksela).
Hypoaesthesia Sciatica 
Često letargija hipoestezija ishijalgija
PHARMACEUTICAL FORM AND CONTENTS Concentrate and solvent for solution for infusion. 
Lijek JEVTANA je koncentrat i otapalo za otopinu za infuziju (sterilni koncentrat).
METHOD OF ADMINISTRATION Dilute with the ENTIRE supplied solvent. 
Razrijediti s CJELOKUPNIM priloženim otapalom.
Delay treatment until neutrophil count is >1,500 cells/mm3, then reduce cabazitaxel dose from 25 mg/m2 to 20 mg/m2. 
> 1500 stanica/mm3, a zatim smanjiti dozu kabazitaksela s 25 mg/m2 na 20 mg/m2.
PVC infusion containers or polyurethane infusion sets should not be used for the preparation and administration of the infusion solution. 
Za pripremu i primjenu otopine za infuziju ne smiju se koristiti infuzijski spremnici od PVC-a niti poliuretanski infuzijski setovi.
Pyrexia 
Hematurija
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturers responsible for batch release 
Nazivi i adrese proizvođača odgovornih za puštanje serije lijeka u promet
Frequency not known (cannot be estimated from the available data): • interstitial lung disease (inflammation of the lungs causing coughing and difficulty breathing). 
• intersticijska bolest pluća (upala pluća koja uzrokuje kašalj i otežano disanje).
• you have kidney problems. 
• ako imate probleme s bubrezima.
Therefore concomitant administration of strong CYP3A inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentin, phenobarbital) should be avoided as a decrease of plasma concentrations of cabazitaxel may occur (see sections 4.2 and 4.4). 
rifampin, rifabutin, rifapentin, fenobarbital) jer može doći do smanjenja koncentracije kabazitaksela u plazmi (vidjeti dijelove 4.2 i 4.4).
Unopened vials 3 years. 
3 godine.
Bone marrow suppression 
Supresija koštane srži
EXP Read the leaflet for the shelf life of the diluted solution. 
Pročitajte Uputu o lijeku za navode o roku valjanosti razrijeđene otopine.
Haematuria 
Nuspojave
Preparation and administration precautions 
Mjere opreza prilikom pripreme i primjene lijeka
The concentrate solution and the solvent should be clear. 
Otopina u bočici s koncentratom i otapalo moraju biti bistri.
Chemical and physical stability of the infusion solution has been demonstrated for 8 hours at ambient temperature (15°C - 30°C) including the 1-hour infusion time and for 48 hours at refrigerated conditions including the 1-hour infusion time. 
(15°C - 30°C), uključujući u to i 1-satnu infuziju te 48 sati ako se čuva u hladnjaku, uključujući u to i
Other laboratory abnormalities 
Ostala laboratorijska odstupanja
• urinary incontinence 
Eastern Cooperative Oncology Group)
cabazitaxel once every three weeks in a randomised open label, controlled phase III study. 
U multicentričnom, multinacionalnom, randomiziranom, otvorenom ispitivanju neinferiornosti faze III
The active substance is cabazitaxel. 
Djelatna tvar je kabazitaksel.
PSA secondary endpoints were positive in the JEVTANA arm. 
Sekundarne mjere ishoda s obzirom na PSA bile su pozitivne u skupini koja je primala lijek JEVTANA.
Secondary endpoints included Progression Free Survival [PFS (defined as time from randomization to tumour progression, Prostatic Specific Antigen (PSA) progression, pain progression, or death due to any cause, whichever occurred first], Tumour Response Rate based on Response Evaluation Criteria in Solid Tumours (RECIST), PSA Progression (defined as a ≥25% increase or >50% in PSA non-responders or responders respectively), PSA response (declines in serum PSA levels of at least 50%), pain progression [assessed using the Present Pain Intensity (PPI) scale from the McGill-Melzack questionnaire and an Analgesic Score (AS)] and pain response (defined as 2-point greater reduction from baseline median PPI with no concomitant increase in AS, or reduction of ≥50% in analgesic use from baseline mean AS with no concomitant increase in pain). 
Prostatic Specific Antigen - prostata specifični antigen) , progresije boli ili smrti zbog bilo kojeg uzroka, štogod se dogodilo prvo], stopa tumorskog odgovora na temelju kriterija za ocjenu odgovora kod solidnih tumora (engl.
Diarrhoea 
Premedikacija
Febrile neutropenia or neutropenic infection 
• bubrežna bolest ili tegobe s bubrezima
Oropharyngeal pain Pneumonia 
Oštećenje bubrežne funkcije
Weight decreased Aspartate aminotransferase increased 
Pretrage gubitak težine povišene vrijednosti aspartat aminotransferaze povišene vrijednosti transaminaza a na temelju laboratorijskih vrijednosti * vidjeti opširnije u daljnjem tekstu
Metabolism and nutrition disorders 
Poremećaji metabolizma i prehrane anoreksija dehidracija hiperglikemija hipokalijemija
How to store JEVTANA 
Kako čuvati lijek JEVTANA
• painful or frequent urination 
• bolno ili učestalo mokrenje
METHOD AND ROUTE(S) OF ADMINISTRATION Single-use vials. 
NAČIN I PUT(EVI) PRIMJENE LIJEKA
Each vial of concentrate contains 60 mg cabazitaxel. 
Jedna bočica koncentrata sadrži 60 mg kabazitaksela.
In a non-inferiority, multicenter, multinational, randomized, open label phase III study (EFC11785 study), 1200 patients with metastatic castration resistant prostate cancer, previously treated with a docetaxel-containing regimen, were randomized to receive either cabazitaxel 25 mg/m2 (n=602) or 20 mg/m2 (n=598) dose. 
(EFC11785 ispitivanje), 1200 bolesnika s metastatskim karcinomom prostate rezistentnim na kastraciju, prethodno liječenih kemoterapijskim protokolom koji je uključivao docetaksel,
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION JEVTANA 60 mg sterile concentrate cabazitaxel 
JEVTANA 60 mg sterilni koncentrat kabazitaksel
Nausea 
Nuspojava
Decreased appetite Vomiting 
Hematurija Astenija Smanjeni apetit
• haemorrhoids 
• grčevi mišića
Haemorrhoids 
Cijepljenje
Muscle spasms Myalgia Musculoskeletal chest pain Flank pain 
Poremećaji mišićno koštanog sustava i vezivnog tkiva bol u leđima artralgija bol u ekstremitetima mišićni spazmi mijalgija mišićno-koštana bol u prsnom košu bol u slabinama
Blood and lymphatic system disorders 
Poremećaji krvi i limfnog sustava neutropenijaa* anemijaa leukopenijaa trombocitopenijaa febrilna neutropenija
Respiratory, thoracic and mediastinal disorders 
Poremećaji dišnog sustava, prsišta i sredoprsja dispneja kašalj orofaringealna bol pneumonija
Conjunctivitis Lacrimation increased 
Statistički značajno veći postotak
Cabazitaxel is minimally excreted through the kidney. 
Bolesnici s oštećenjem bubrežne funkcije Kabazitaksel se minimalno izlučuje putem bubrega.
Slovenija sanofi-aventis d.o.o. 
Ελλάδα sanofi-aventis AEBE
Tofacitinib - Angioedema (EPITT no 18904) 
Tofacitinib - angioedem (EPITT br. 18904)
Posology and method of administration, and/or 4.4. 
4.2. Doziranje i način primjene, i/ili 4.4.
Insulin (pre-filled pens and cartridges): insulin aspart; insulin bovine; insulin degludec; insulin degludec, insulin aspart; insulin degludec, liraglutide; insulin detemir; insulin glargine; insulin glulisine; insulin human (rDNA); insulin human, insulin isophane; insulin lispro; insulin porcinePotential increased risk of medication error associated with withdrawing insulin from pre-filled pens and cartridges, leading to dysglycaemia (EPITT no 18893) 
Inzulin (napunjene brizgalice i ulošci): inzulin aspart; goveđi inzulin; inzulin degludek; inzulin degludek, inzulin aspart; inzulin degludek, liraglutid; inzulin detemir; inzulin glargin; inzulin glulizin; humani inzulin (rDNK); humani inzulin, inzulin izofan; inzulin lispro; svinjski insulinPotencijalni povećani rizik od medikacijske pogreške povezane s izvlačenjem inzulina iz napunjenih brizgalica i uložaka, koja uzrokuje disglikemiju (EPITT br. 18893)
Allergic reactions included angioedema and urticaria; serious reactions have occurred. 
Alergijske reakcije uključivale su angioedem i urtikariju; javile su se ozbiljne reakcije.
Adopted at the 27-30 November 2017 PRAC 
Usvojeno na sjednici PRAC-a 27. - 30. studenoga 2017.
Frequency ‘not known': hypersensitivity; angioedema; urticaria 
Poremećaji imunološkog sustava Učestalost „nepoznato”: preosjetljivost; angioedem; urtikarija
If any serious allergic or anaphylactic reaction occurs, tofacitinib should be discontinued immediately. 
U slučaju nastanka bilo koje ozbiljne alergijske ili anafilaktičke reakcije, potrebno je odmah prestati s uzimanjem tofacitiniba.
New product information wording - Extracts from PRAC recommendations on signals EMA/PRAC/611010/2017 
Novi tekst informacija o lijeku - izvadci iz preporuka PRAC-a vezanih uz signale EMA/PRAC/813952/2017
Other side effects which have been observed with XELJANZ are listed below. 
Druge nuspojave koje su zabilježene s lijekom XELJANZ navedene su u nastavku.
In post-marketing experience, cases of hypersensitivity associated with tofacitinib administration have been reported. 
U razdoblju nakon stavljanja lijeka u promet prijavljeni su slučajevi preosjetljivosti povezani s primjenom tofacitiniba.
Special warnings and precautions for use 
Posebna upozorenja i mjere opreza pri uporabi Preosjetljivost
Special precautions for disposal and other handling The following text and any related package leaflet text should be removed: ‘If the <pen / infusion pump> malfunctions (see instructions for using the pen / infusion pump), the solution may be drawn from the cartridge into a syringe (suitable for an insulin with 100 units/mL) and injected.' 
Potrebno je ukloniti sljedeći tekst i njemu odgovarajući tekst u uputi o lijeku: „Ako <brizgalica / infuzijska pumpa> ne radi ispravno (vidjeti upute za uporabu brizgalice / infuzijske pumpe), otopina inzulina se može iz uloška uvući u štrcaljku (prikladnu za inzulin koncentracije 100 jedinica/ml) i injicirati.”
<If administration by syringe, <intravenous injection> or <infusion pump> is necessary, a vial should be used.>> 
< Ako je potrebna primjena pomoću štrcaljke, <intravenske injekcije> ili <infuzijske pumpe> potrebno je koristiti bočicu.>>
Not known (frequency cannot be estimated from the available data): hives (itchy, bumpy rash) 
Nepoznato (učestalost se ne može procijeniti iz dostupnih podataka): koprivnjača (uzdignuti osip koji svrbi)
Special warnings and precautions for use <<Product name in cartridges> is only suitable for subcutaneous injections from a reusable pen. 
Posebna upozorenja i mjere opreza pri uporabi <<Naziv lijeka u ulošcima> je prikladan samo za potkožne injekcije iz brizgalice za višekratnu uporabu.
Standard (100 units/mL) and lower (< 100 units/mL) strength insulin products The text to be adapted to individual products is in bold. 
Inzulinski lijekovi standardne (100 jedinica/ml) i manje (< 100 jedinica/ml) jačine
<Product name in pre-filled pen> is only suitable for injecting just under the skin. 
<Naziv lijeka u napunjenoj brizgalici> je prikladan samo za ubrizgavanje neposredno pod kožu.
<<Product name in pre-filled pen> is only suitable for subcutaneous injections. 
<<Naziv lijeka u napunjenoj brizgalici> je prikladan samo za potkožne injekcije.
How to use <product name> <Product name in cartridges> is only suitable for injecting just under the skin using a reusable pen. 
Što morate znati prije nego počnete primjenjivati <naziv lijeka>, i 3. Kako primjenjivati <naziv lijeka> <Naziv lijeka u ulošcima> je prikladan samo za ubrizgavanje neposredno pod kožu pomoću brizgalice za višekratnu uporabu.
Rabbits need to be revaccinated every year. 
Kuniće treba ponovo cijepiti svake godine.
This overview was last updated in September 2019. 
Pregled je posljednji put ažuriran u rujnu 2019.
Protection starts at three weeks and lasts for one year. 
Zaštita započinje u trećem tjednu i traje godinu dana.
It is given to rabbits from five weeks of age as a single injection under the skin. 
Daje se kunićima starijima od pet tjedana tako da im se ubrizga jednokratna injekcija pod kožu.
The virus causes swelling and discharge from the eyes, nose and bottom with most rabbits dying within 10 - 14 days. 
Virus uzrokuje oticanje i iscjedak iz oka, nosa i stražnjice s tim da većina kunića ugiba unutar razdoblja od 10 do 14 dana.
The swelling resolves completely by 3 weeks after vaccination. 
Oteklina potpuno nestaje 3 tjedna nakon cijepljenja.
RHD, caused by classical RHD virus (RHDV1) and RHD type 2 virus (RHDV2), leads to blood clots in major organs such as the heart, lungs and kidneys leading to heart and respiratory failure when the heart and lungs do not work properly. 
Hemoragična bolest kunića koju uzrokuje klasični RHD virus (RHDV1) i RHD virus tipa 2 (RHDV2) rezultira stvaranjem krvnih ugrušaka u glavnim organima poput srca, pluća i bubrega što izaziva zatajenje srca i respiratorno zatajenje kada srce i pluća ne rade pravilno.
Antibody levels increased for up to six weeks following vaccination and stayed at this level for 12 months. 
Razine antitijela povećale su se do šestog tjedna nakon cijepljenja i ostale na toj razini 12 mjeseci.
Further information on Nobivac Myxo-RHD Plus can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/nobivac-myxo-rhd-plus. 
Više informacija o VMP-u Nobivac Myxo-RHD Plus nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/veterinary/EPAR/nobivac-myxo-rhd-plus.
The most common side effects with Nobivac Myxo-RHD Plus (which may affect up to 1 in 10 animals) are a short-lived temperature increase of 1 to 2 °C and a small, non-painful swelling (maximum 2 cm diameter) at the injection site within the first two weeks after vaccination. 
Najčešće nuspojave VMP-a Nobivac Myxo-RHD Plus (mogu se javiti u manje od 1 na 10 životinja) su prolazni porast temperature od 1 do 2 °C i mala oteklina na mjestu iniciranja koja nije bolna (najvećeg promjera do 2 cm) u prva dva tjedna nakon cijepljenja.
Four laboratory studies were conducted in young rabbits that showed protection began three weeks after vaccination and lasted 12 months against RHDV1 and RHDV2. 
Provedena su četiri laboratorijska ispitivanja na mladim kunićima kojima se utvrdilo da je zaštita od virusa RHDV1 i RHDV2 započela tri tjedna nakon cijepljenja i trajala 12 mjeseci.
For myxoma virus, rabbits were tested for antibodies only. 
Kada je riječ o miksoma virusu kunići su testirani samo na antitijela.
The withdrawal period for meat from rabbits treated with Nobivac Myxo-RHD Plus is ‘zero' days, which means that there is no mandatory waiting time. 
Razdoblje karencije za meso kunića liječenih VMP-om Nobivac Myxo-RHD Plus iznosi „nula dana”, odnosno nema obveznog razdoblja čekanja.
When a rabbit is given the vaccine, the immune system recognises the weakened viruses in the vaccine as ‘foreign' and makes antibodies against both the myxoma virus and the RHD virus proteins. 
Kad kunić primi cjepivo, imunosni sustav prepoznaje oslabljene viruse u cjepivu kao strano tijelo i proizvodi protutijela i protiv miksoma virusa i protiv proteina RHD virusa.
These studies showed that rabbits that were vaccinated with Nobivac Myxo-RHD had fewer signs of myxomatosis, more antibodies against RHDV1 virus in their blood and a lower death rate than unvaccinated rabbits. 
Tim se ispitivanjima utvrdilo da su kunići koji su bili cijepljeni VMP-om Nobivac MyxoRHD imali manje znakova miksomatoze, više antitijela protiv virusa RHDV1 u krvi i manju stopu smrtnosti od kunića koji nisu cijepljeni.
Myxomatosis is caused by the myxoma virus and is spread between rabbits by close contact and biting insects such as fleas and mosquitoes. 
Miksomatozu uzrokuje miksoma virus koji se među kunićima širi bliskim kontaktom i ugrizima insekata poput buha i komaraca.
These viruses have been modified so that they also produce proteins from the outer coat of either RHDV1 (strain 009) or RHDV2 (strain MK1899). 
Ti su virusi modificirani tako da proizvode i proteine iz vanjske ovojnice virusa RHDV1 (soj 009) ili virusa RHDV2 (soj MK1899).
In addition, the company also presented field studies with the already authorised vaccine Nobivac Myxo-RHD which contains live myxoma vectored RHD virus strain 009 only. 
Osim toga, tvrtka je dostavila terenska ispitivanja u vezi s već odobrenim cjepivom Nobivac Myxo-RHD koje sadrži samo živi miksoma virus vektorskog RHD soja 009.
Nobivac Myxo-RHD Plus is a vaccine. 
Nobivac Myxo-RHD Plus je cjepivo.
Nobivac Myxo-RHD Plus is available as a freeze dried powder (lyophilisate) and solvent for suspension for injection and can only be obtained with a prescription. 
Nobivac Myxo-RHD Plus dostupan je kao smrznuti osušeni prašak (liofilizat) i otapalo za suspenziju za injekciju i izdaje se samo na veterinarski recept.
Nobivac Myxo-RHD Plus contains small amounts of weakened forms of the myxoma virus that causes myxomatosis. 
Nobivac Myxo-RHD Plus sadrži male količine oslabljenih oblika miksoma virusa koji uzrokuje miksomatozu.
The European Medicines Agency decided that Nobivac Myxo-RHD Plus's benefits are greater than its risks and it can be authorised for use in the EU. 
Europska agencija za lijekove zaključila je da koristi od VMP-a Nobivac Myxo-RHD Plus nadmašuju s njim povezane rizike te se može izdati odobrenje za njegovu primjenu u EU-u.
For more information about using Nobivac Myxo-RHD Plus, see the package leaflet or contact your veterinarian or pharmacist. 
Za dodatne informacije o primjeni VMP-a Nobivac Myxo-RHD Plus pogledajte uputu o VMP-u, odnosno obratite se svom veterinaru ili ljekarniku.
Nobivac Myxo-RHD Plus is a vaccine used in rabbits to reduce death and clinical signs due to myxomatosis and rabbit haemorrhagic disease (RHD). 
Nobivac Myxo-RHD Plus je cjepivo koje se daje kunićima kako bi se smanjila smrtnost i klinički znakovi uslijed miksomatoze i hemoragične bolesti kunića (RHD).
Nobivac Myxo-RHD Plus contains live myxoma vectored RHD virus strains 009 and MK1899. 
Nobivac Myxo-RHD Plus sadrži živi miksoma virus vektorskih RHD sojeva 009 i MK1899.